Logo image of BCART.BR

BIOCARTIS GROUP NV (BCART.BR) Stock Fundamental Analysis

EBR:BCART - Euronext Brussels - BE0974281132 - Common Stock - Currency: EUR

0.29  +0.01 (+1.75%)

Fundamental Rating

2

BCART gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 54 industry peers in the Health Care Equipment & Supplies industry. BCART may be in some trouble as it scores bad on both profitability and health. BCART is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BCART had negative earnings in the past year.
In the past year BCART has reported a negative cash flow from operations.
BCART had negative earnings in each of the past 5 years.
BCART had a negative operating cash flow in each of the past 5 years.
BCART.BR Yearly Net Income VS EBIT VS OCF VS FCFBCART.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

BCART has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCART.BR Yearly ROA, ROE, ROICBCART.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 100 -100 200

1.3 Margins

BCART has a Gross Margin of 48.16%. This is comparable to the rest of the industry: BCART outperforms 42.59% of its industry peers.
In the last couple of years the Gross Margin of BCART has declined.
The Profit Margin and Operating Margin are not available for BCART so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.82%
GM growth 5Y-3.85%
BCART.BR Yearly Profit, Operating, Gross MarginsBCART.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

BCART does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BCART has been increased compared to 1 year ago.
BCART has a better debt/assets ratio than last year.
BCART.BR Yearly Shares OutstandingBCART.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
BCART.BR Yearly Total Debt VS Total AssetsBCART.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -5.89, we must say that BCART is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BCART (-5.89) is worse than 94.44% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.89
ROIC/WACCN/A
WACC5.17%
BCART.BR Yearly LT Debt VS Equity VS FCFBCART.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 1.65 indicates that BCART should not have too much problems paying its short term obligations.
BCART has a Current ratio (1.65) which is comparable to the rest of the industry.
BCART has a Quick Ratio of 1.20. This is a normal value and indicates that BCART is financially healthy and should not expect problems in meeting its short term obligations.
BCART has a Quick ratio (1.20) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.2
BCART.BR Yearly Current Assets VS Current LiabilitesBCART.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for BCART have decreased by -1.55% in the last year.
Looking at the last year, BCART shows a quite strong growth in Revenue. The Revenue has grown by 19.08% in the last year.
The Revenue has been growing by 22.36% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.11%
Revenue 1Y (TTM)19.08%
Revenue growth 3Y15.36%
Revenue growth 5Y22.36%
Sales Q2Q%17.8%

3.2 Future

Based on estimates for the next years, BCART will show a very strong growth in Earnings Per Share. The EPS will grow by 24.29% on average per year.
The Revenue is expected to grow by 21.39% on average over the next years. This is a very strong growth
EPS Next Y36%
EPS Next 2Y31.91%
EPS Next 3Y24.29%
EPS Next 5YN/A
Revenue Next Year3.76%
Revenue Next 2Y16.6%
Revenue Next 3Y21.39%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BCART.BR Yearly Revenue VS EstimatesBCART.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
BCART.BR Yearly EPS VS EstimatesBCART.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCART. In the last year negative earnings were reported.
Also next year BCART is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCART.BR Price Earnings VS Forward Price EarningsBCART.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCART.BR Per share dataBCART.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

BCART's earnings are expected to grow with 24.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.91%
EPS Next 3Y24.29%

More info and screens

0

5. Dividend

5.1 Amount

BCART does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCARTIS GROUP NV

EBR:BCART (9/22/2023, 7:00:00 PM)

0.29

+0.01 (+1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap27.24M
Analysts84.44
Price Target1.12 (286.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-26.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-60%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-18.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.47
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.1
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0.61
BVpS-0.32
TBVpS-0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.16%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.82%
GM growth 5Y-3.85%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.48%
Cap/Sales 3.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.2
Altman-Z -5.89
F-Score4
WACC5.17%
ROIC/WACCN/A
Cap/Depr(3y)29.2%
Cap/Depr(5y)49.97%
Cap/Sales(3y)6.05%
Cap/Sales(5y)9.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.11%
EPS Next Y36%
EPS Next 2Y31.91%
EPS Next 3Y24.29%
EPS Next 5YN/A
Revenue 1Y (TTM)19.08%
Revenue growth 3Y15.36%
Revenue growth 5Y22.36%
Sales Q2Q%17.8%
Revenue Next Year3.76%
Revenue Next 2Y16.6%
Revenue Next 3Y21.39%
Revenue Next 5YN/A
EBIT growth 1Y24.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.9%
EBIT Next 3Y29.4%
EBIT Next 5YN/A
FCF growth 1Y32.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.74%
OCF growth 3YN/A
OCF growth 5YN/A